A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Industrials, Financials
Tech for Global, Globalization Footprints of the Established and the New
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM